Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Addressing disease progression in EGFRmut+ NSCLC patients

Date

08 Oct 2016

Session

Poster Display

Presenters

Roxana Tudor

Citation

Annals of Oncology (2016) 27 (6): 416-454. 10.1093/annonc/mdw383

Authors

R. Tudor1, K. Kopciuk2, A. D'Silva1, D. Brenner2, D. Morris3, D.G. Bebb3

Author affiliations

  • 1 Medical Oncology, Faculty of Medicine, University of Calgary, T2N 2N4 - Calgary/CA
  • 2 Cancer Epidemiology And Prevention Research, Cancer Control Alberta, T2S3C3 - Calgary/CA
  • 3 Medical Oncology, Tom Baker Cancer Centre, T2N 4N2 - Calgary/CA
More

Resources

Abstract 2592

Background

Although EGFR-Tyrosine Kinase Inhibitors (TKIs) have improved disease management in EGFR mutation-positive NSCLC patients, all patients experience disease progression (PD) and ultimately die. In current practice, EGFR-TKIs are often continued beyond PD (RECIST1.1), however optimal management at PD remains ambiguous. We set out to study the survival differences and patient characteristics associated with continuation vs discontinuation of EGFR-TKI at PD retrospectively at a single institution: the Tom Baker Cancer Centre, AB Canada (2010-2014).

Methods

EGFRmut+ NSCLC patients treated with an EGFR-TKI were retrospectively analyzed. Demographic and clinical data, EGFR mutation type, treatment-variations at PD (chemotherapy, radiation, continuation with EGFR-TKI) were collected. SPSS-v19 was used to generate Kaplan-Meier survival curves. Progression-free survival (PFS) (time from initiating EGFR-TKI to PD) and time-to-complete EGFR-TKI-cessation (time from initiating EGFR-TKI to cessation of TKI completely, if extended beyond PD), were assessed.

Results

127 EGFRmut+ NSCLC patients received EGFR-TKIs. 106/127 (83%) developed PD (RECIST 1.1) (64.8% F/35.2% M; 95% adenocarcinoma; smoking history: 47%; ex 19 del/L858R/other: 45.7%/ 35.4%/ 18.9 %). Median PFS was 7.9 months, while median overall survival (mOS) was 17.3 months. A log-rank test showed a statistical significant difference in mOS between exon 19 deletion and L858R (22.6months vs 15.0months; 95% CI, 14.8m to 21.9m; P-value = 0.014). At PD, 54.7% continued EGFR-TKI treatment; 45.2% received other forms of treatments. Female gender, PD with solitary-lesions and younger age are associated with EGFR-TKI continuation at PD.

Conclusions

This study confirms the difference in survival of exon 19 del vs L858R patients when treated with an EGFR-TKI. Additionally, it is common practice for oncologists to continue TKI treatment beyond PD. Further analysis, by time-to-complete EGFR-TKI cessation, will provide a more stratified base for future clinical-trials exploring treatment at EGFR-TKI-PD.

Clinical trial identification

Not Applicable

Legal entity responsible for the study

University of Calgary

Funding

AstraZeneca

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings